|Articles|January 29, 2021
Top questions answered on challenging HCP assays
Author(s)Cytiva
Cytiva experts answer your top questions about challenging host cell protein assays to improve risk mitigation.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
2
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
3
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
4
Implementing Automation and Flexible Design for Allogeneic Manufacturing
5
